MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

2011275 citationsJournal Articlegreen Open Access

Authors

N.V. Rajeshkumar · Spanish National Cancer Research Centre

Elizabeth De Oliveira · Johns Hopkins University

Niki A. Ottenhof · Johns Hopkins University

James Watters · Universidad San Pablo

David G. Brooks · Universidad San Pablo CEU

Tim Demuth · Universidad San Pablo CEU

Stuart D. Shumway

Abstract

These results indicate that MK-1775 selectively synergizes with GEM to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 17, Issue 9, pp. 2799-2806

DOI: 10.1158/1078-0432.ccr-10-2580

Field-Weighted Citation Impact: 9.28